Compositions and methods for forming composites of polymer fibers, yarns, and textiles having enhanced elastocaloric and twistocaloric performance are provided herein. The composites can permit reversible temperature shifts within the materials, and can be used, for example, in energy conversion and thermal storage systems. These composites can be formulated by melt spinning the polymer fibers and using combinations of twisting and stretching of the polymer fibers. The fibers can include, for example, a base polymer that can be amorphous, or substantially amorphous, and desired alignment can occur, for example, by performing one or more of the various provided for techniques. In at least some embodiments, the composite materials can be further enhanced by including one or more phase change materials (PCMs), such as by cross-linking the one or more PCMs with one or more polymers and/or directly attaching the PCM(s) to the polymer(s).
D01F 6/30 - Monocomponent man-made filaments or the like of synthetic polymersManufacture thereof from copolymers obtained by reactions only involving carbon-to-carbon unsaturated bonds comprising olefins as the major constituent
D02G 3/44 - Yarns or threads characterised by the purpose for which they are designed
2.
SITE-SELECTIVE CONJUGATION OF A PHARMACEUTICAL AGENT TO AN ANTIBODY USING AN AFFINITY PEPTIDE
The present disclosure provides site-selective conjugation of a pharmaceutical agent to an antibody using an affinity peptide. The antibody-pharmaceutical agent conjugates may be useful in treating, preventing, or diagnosing diseases in subjects.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 1/107 - General processes for the preparation of peptides by chemical modification of precursor peptides
3.
PALLADIUM-PLATINUM OXIDE CATALYST FOR AQUEOUS ELECTROCHEMICAL DIRECT EPOXIDATION
Methods and systems for the electrochemical epoxidation of alkenes to generate an epoxide are described herein. Said methods and systems comprise: contacting an anode comprising an oxygen atom transfer electrocatalyst with an alkene in the presence of an electrolyte comprising water; applying a voltage to the anode and a cathode to generate the epoxide; wherein the oxygen atom transfer electrocatalyst comprises an at least partially oxidized palladium-platinum alloy characterized by the formula FX1: PdyPtzOx; wherein y is greater than 0 and less than 1; z is greater than 0 and less than 1; wherein the sum of y and z is equal to 1; and x is selected from the range of 0 to 2. The methods and systems disclosed herein comprise a significant advancement in the electrocatalytic epoxidation of alkenes in aqueous and mixed electrolytes using water as the oxygen atom transfer source.
C25B 9/23 - Cells comprising dimensionally-stable non-movable electrodesAssemblies of constructional parts thereof with diaphragms comprising ion-exchange membranes in or on which electrode material is embedded
C25B 11/075 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound
4.
PALLADIUM-PLATINUM OXIDE CATALYST FOR AQUEOUS ELECTROCHEMICAL DIRECT EPOXIDATION
yzxx; wherein y is greater than 0 and less than 1; z is greater than 0 and less than 1; wherein the sum of y and z is equal to 1; and x is selected from the range of 0 to 2. The methods and systems disclosed herein comprise a significant advancement in the electrocatalytic epoxidation of alkenes in aqueous and mixed electrolytes using water as the oxygen atom transfer source.
C25B 11/097 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of at least one catalytic element and at least one catalytic compoundElectrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of two or more catalytic elements or catalytic compounds comprising two or more noble metals or noble metal alloys
Systems and methods for predicting a medical trait in an individual are provided. The techniques include obtaining genomic data including information indicative of genetic variants present in a genome of the individual and calculating, using an at least one processor and a trained computational model, a trait score based on the information indicative of the genetic variants, wherein the trained computational model was obtained by training a first computational model using data describing phenotypes, genotypes, and/or phenotype-genotype relationships for a population including admixed individuals of multiple ancestries. The trait score may be used to alter a course of medical treatment of the individual and/or to implement a clinical trial.
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
G16B 35/00 - ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
A system for parallelized computation of a product of a matrix and an input vector includes a plurality of processing cores, a plurality of memory devices, and a controller. Each processing core is configured to: (a) receive and store a plurality of matrix elements in at least one memory device; (b), during a first set of clock cycles, receive at least one vector element of the input vector from the controller; (c) multiply the at least one vector element with at least one matrix element stored in the at least one memory device associated with the processing core; (d) add the result of the multiplication to a value of at least one accumulator and store the result of the addition in the accumulator; (e) repeat steps (b) through (d) during at least a second set of clock cycles; (f) transmit the value of the accumulator to the controller.
Described in certain example embodiments herein are programmable nuclease-peptidase compositions, systems, and methods for the manipulation of nucleic acids and/or polypeptides. In some embodiments, the programmable nuclease-peptidase composition comprises a repeat-associated mysterious protein (RAMP) polypeptide; a guide molecule capable of forming a RAMP-guide molecule complex with the RAMP polypeptide and directing sequence specific binding of the complex to a target polynucleotide; and a peptidase capable of binding to the RAMP polypeptide, the guide molecule, or further complexing with the RAMP-guide molecule complex, wherein binding of the RAMP-guide molecule complex to the target polynucleotide initiates binding and/or interaction of the peptidase with a target polypeptide.
The present disclosure provides compositions, reagents, and methods for producing capped, circular RNA molecules, circularized RNA molecules, and in particular, circularized mRNA molecules encoding a polypeptide such as a therapeutic protein.
C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes
Systems and methods for nerve repair can include a polymer configured to form an elongated conduit to receive an in vivo nerve therein and provide a mechanical stabilization to the in vivo nerve. The polymer can be configured to degrade upon being subjected to a dissolution solution to remove the mechanical stabilization from the in vivo nerve.
A61B 17/11 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for performing anastomosisButtons for anastomosis
A61B 17/00 - Surgical instruments, devices or methods
Targeted metal ions can be harnessed from brines by feeding a mixed, aqueous, brine stream including the targeted metal ions and other dissolved ions through a water-recovery module on a first side of a first membrane. In the water-recovery module, water is passed from a monovalent-ion-rich stream on a second side of the first membrane through the first membrane into the mixed, aqueous, brine stream on the first side of the first membrane to produce a diluted, mixed, aqueous, brine stream. The diluted, mixed, aqueous, brine stream is then passed through a valency-selective ion-separation module to produce the monovalent-rich stream, and a multivalent-ion-rich stream, one of which includes a concentration of the targeted metal ions.
B01D 61/00 - Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltrationApparatus, accessories or auxiliary operations specially adapted therefor
C02F 1/44 - Treatment of water, waste water, or sewage by dialysis, osmosis or reverse osmosis
C02F 1/469 - Treatment of water, waste water, or sewage by electrochemical methods by electrochemical separation, e.g. by electro-osmosis, electrodialysis, electrophoresis
C02F 9/00 - Multistage treatment of water, waste water or sewage
Hybrid hydrogels for organogenesis support organogenesis from mammalian cells, including human cells. The hybrid hydrogels typically include a network of crosslinked branched synthetic polymers including a branched polyalkylene oxide polymer and a thiolated extracellular matrix polymer, preferably hyaluronic acid. These polymers are crosslinked to adhesion ligand peptides. Also provided are methods of making the hybrid hydrogels and methods of using the hybrid hydrogels for organogenesis.
Described herein are circuits and systems with fixed impedances (e.g., arranged in an array) that, in accordance with certain embodiments, may be programmable for performing multiplication or similar functions. Some embodiments of the present disclosure provide an integrated circuit with an array of fixed impedances coupled to and between conductive portions of respective layers of the integrated circuit, at least some of the fixed impedances having different fixed impedance values. Some embodiments of the present disclosure provide an integrated circuit with an array of fixed impedances coupled to and between an input terminal and an output terminal of the integrated circuit, the array having fixed impedance values programmed for multiplying a value of an input signal received at the input terminal to produce an output at the output terminal. Embodiments of the present disclosure may be produced at high scale, efficiently, and reliably by leveraging existing integrated circuit technologies.
G06F 9/30 - Arrangements for executing machine instructions, e.g. instruction decode
G06G 7/163 - Arrangements for performing computing operations, e.g. amplifiers specially adapted therefor for multiplication or division using a variable impedance controlled by one of the input signals, variable amplification or transfer function
The present disclosure describes circuits and systems for performing multiplication that, in accordance with certain embodiments, are programmable, fast, reliable, and highly-scalable. Some embodiments of the present disclosure provide integrated circuit structures with parallel-coupled switchable impedances configured to perform multiplication. Some embodiments of the present disclosure provide scalar multiplication circuits that are controllable using selectable paths through the circuit. Embodiments of the present disclosure may be produced at high scale both efficiently and reliably by leveraging existing integrated circuit and memory technologies.
G06F 7/575 - Basic arithmetic logic units, i.e. devices selectable to perform either addition, subtraction or one of several logical operations, using, at least partially, the same circuitry
G06F 7/544 - Methods or arrangements for performing computations using exclusively denominational number representation, e.g. using binary, ternary, decimal representation using non-contact-making devices, e.g. tube, solid state deviceMethods or arrangements for performing computations using exclusively denominational number representation, e.g. using binary, ternary, decimal representation using unspecified devices for evaluating functions by calculation
G06F 7/57 - Arithmetic logic units [ALU], i.e. arrangements or devices for performing two or more of the operations covered by groups or for performing logical operations
This invention provides compositions, reagents, methods, and kits for producing derivatized RNA molecules, particular mRNA molecules encoding a polypeptide and in particular a therapeutic protein, derivatized by linkage to a peptide, aptamer, synthetic DNA or RNA oligonucleotide or molecular probe, capable of targeting the derivatized RNA molecules to a particular subcellular location in a target cell.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes
Articles, systems, and methods related to the separation of at least a first species from at least a second species using nanoporous membranes are generally described.
The present disclosure provides, in some aspects, a humanized immunodeficient mouse model of human fibrosis. A humanized immunodeficient mouse model provided herein may be used, for example, for modeling human fibrosis, predicting human fibrosis, and testing putative fibrosis treatments.
Some aspects of the present disclosure are related to articles for measuring electrical signals internal to a subject, e.g., of the gastrointestinal tract (GI tract). The articles, in some embodiments, are ingestible and/or implantable. In some embodiments, the articles comprise a substrate comprising a plurality of electrodes, the substrate having a Young's elastic modulus of greater than or equal to 0.01 MPa and less than or equal to 200 MPa. In some such cases, the Young's elastic modulus of the substrate facilitates elastic recoil of the substrate such that at least a portion of the plurality of electrodes contact a surface of a tissue at the location internal to the subject (e.g., the GI tract) and thus facilitate measurement of electrical signals at the location internal to the subject. Other aspects are related to methods of using the articles, for example, to monitor electrical signals from the location internal to the subject.
Described is a device having three-dimensional (3D) integration of a DRAM die and processor ASIC. Such an integrated device achieves much higher memory bandwidth and low memory access power consumption than prior art devices while still retaining the high capacity and low cost of DRAMs. The devices and techniques described herein can result in much higher computational throughput, higher power efficiency, and lower cost per throughput than conventional processors while still providing the high memory capacity necessary to be able to work on large problems.
H01L 25/04 - Assemblies consisting of a plurality of individual semiconductor or other solid-state devices all the devices being of a type provided for in a single subclass of subclasses , , , , or , e.g. assemblies of rectifier diodes the devices not having separate containers
H10B 80/00 - Assemblies of multiple devices comprising at least one memory device covered by this subclass
This disclosure provides compositions and methods for treating subjects having cancer. It is based, in part, on an improved ability to modulate and orchestrate the activity of different cytokines, and thereby mount an effective immune response at a primary tumor site (i.e., a primary site of injection, that may also be but need not be the primary site of cancer development in the subject) but also at distal tumor sites (i.e., metastatic lesions). Provided herein are methods that employ localized administration regimens for cytokine fusion proteins that target the universal leukocyte receptor CD45. The cytokine fusion proteins comprise the cytokine of interest, namely IL-12 or IL-15, fused to a CD45-specific binding moiety. The Examples demonstrate that such immunocytokine fusions can be used to achieve a highly efficacious and non-toxic cytokine therapy that elicits complete responses at injected lesions as well as distal un-injected lesions.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Tissue access systems and methods for the minimally invasive delivery of hardware into tissues and organs are provided. The systems include an applicator charged with a hardware payload having a programmable trajectory projection cap. The trajectory projection cap has internal channels configured to redirect hardware subcomponents in a predetermined direction and at a predetermined angle to deliver the hardware subcomponents to a specific position in tissue, to pass through specific tissue, or to avoid specific tissue.
Described herein are engineered antigen presenting cells that can be capable of modulating a target T-cell in a T-cell antigen specific manner. In some embodiments, the engineered APCs can include a modified antigen presentation pathway. Also described herein are methods of making and using the engineered antigen presenting cells.
C07K 14/74 - Major histocompatibility complex [MHC]
C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
22.
PARTICLES WITH COVALENTLY LIPID-BOUND IMMUNOSTIMULATORY AGENTS
Disclosed herein are particles, compositions, methods, and kits of particles comprising immunostimulatory agents that can be useful in the treatment or prevention of diseases, such as cancer.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A system and method for interactive visualization of knowledge provided by large language models (LLMs) is disclosed. The system advantageously organizes LLM responses into an interactive knowledge graph visualization. Additionally, the system enables the user to interactively expand a knowledge graph by further prompting the LLM to provide additional responses that include additional knowledge. When applied to the task of design ideation, the interactive knowledge graph visualization helps to mitigate design fixation and enhances the overall efficiency, quality, quantity, and depth of concepts in the ideation process.
Disclosed herein arc particles, compositions, methods, and kits of particles comprising immunostimulatory agents that can be useful in the treatment or prevention of diseases, such as cancer.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
Described is a method for reducing parasitic ZZ interactions using third-order dispersive interactions and its implementation in superconducting qubits. In one example embodiment, a system comprises a first fluxonium qubit; a second fluxonium qubit; and a resonant circuit coupled to both the first fluxonium qubit and the second fluxonium qubit according to respective coupling strengths, wherein interactions between the resonant circuit and the first and second qubits alters at least one energy levels of computational states of the system to thereby reduce an always-on ZZ interaction.
Some aspects of the present disclosure are related to articles for measuring electrical signals internal to a subject, e.g., of the gastrointestinal tract (GI tract). The articles, in some embodiments, are ingestible and/or implantable. In some embodiments, the articles comprise a substrate comprising a plurality of electrodes, the substrate having a Young's elastic modulus of greater than or equal to 0.01 MPa and less than or equal to 200 MPa. In some such cases, the Young's elastic modulus of the substrate facilitates elastic recoil of the substrate such that at least a portion of the plurality of electrodes contact a surface of a tissue at the location internal to the subject (e.g., the GI tract) and thus facilitate measurement of electrical signals at the location internal to the subject. Other aspects are related to methods of using the articles, for example, to monitor electrical signals from the location internal to the subject.
An initial protein sequence is identified and varied to generate a plurality of variants. An activity of the plurality of protein sequences is measured quantitatively. Each of the plurality of protein sequences is provided as an input to a large language model (LLM) to generate a corresponding plurality of embeddings in a latent space. A subset of the plurality of embeddings is used to train a top layer model. The plurality of embeddings are provided as inputs to the top layer model to generate outputs representing predictions of the activity of the plurality of protein sequences. A subset of the plurality of protein sequences is selected based on the top layer model outputs. The method repeats, with the selected subset of the plurality of protein sequences playing the role of the initial protein sequence in the initial iteration, until some termination criterion is satisfied.
in situin situin situ after injection into the tissue of the subject, wherein molecules of the drug are released via surface erosion from the implant. The implant may include a packing efficiency above 97%, and the drug may comprise microcrystals. The composition may be injectable by hand using a needle with a gauge of in a range of 16-30G, wherein the injection by hand includes less than 64 N of force at a 6 mL/minute injection rate.
A device configured to be implanted in a subject includes a sensing module, a therapeutic module, and a battery. The sensing module includes at least two of an accelerometer, an electrocardiogram (ECG) sensor, a photoplethysmogram (PPG) sensor, and a temperature sensor. The therapeutic module includes a drug reservoir and a reciprocating pump. The battery powers the sensing module and the therapeutic module. The sensing module is configured to detect a biological event in the subject and, upon detection of the biological event, send a signal to the therapeutic module. The therapeutic module is configured to receive the signal from the sensing module and, upon receiving the signal, administer a drug to the subject from the drug reservoir via the pump.
Methods, compositions, and kits of parts for preventing or reducing wound contraction. Methods that may include reducing or eliminating a contractile force applied at a tissue wound site by a continuous myofibroblast network. Compositions may include a biocompatible liquid, and a myofibroblast receptor binding agent dispersed in the biocompatible liquid. Kits of parts may include a reservoir and an applicator, such as a nozzle, needle, brush, dropper, or roller.
Disclosed herein are systems and techniques for seamless and scalable piezoresistive matrix-based intelligent textile development using digital flat-bed and circular knitting machines. Disclosed embodiments allow for combining and customizing functional conductive and polyester and spandex yarns, thus allowing for designing the aesthetics and architecting and engineering both the electrical and mechanical properties of the pressure sensing textile. In addition, by incorporating a melting fiber, disclosed embodiments allow for shaping and personalizing a three-dimensional piezoresistive fabric structure that can conform to the human body through thermoforming principles.
D04B 15/66 - Devices for determining or controlling patterns
D04B 1/16 - Other fabrics or articles characterised primarily by the use of particular thread materials synthetic threads
D04B 1/24 - Weft knitting processes for the production of fabrics or articles not dependent on the use of particular machinesFabrics or articles defined by such processes specially adapted for knitting goods of particular configuration wearing apparel
G06F 3/041 - Digitisers, e.g. for touch screens or touch pads, characterised by the transducing means
G06F 3/045 - Digitisers, e.g. for touch screens or touch pads, characterised by the transducing means using resistive elements, e.g. a single continuous surface or two parallel surfaces put in contact
Disclosed embodiments may include systems and methods of a permanent magnet (PM) hybrid core inductor and fabrication methods thereof. The permanent magnet hybrid core may include a first set of members comprising a soft magnetic material, the first set of members forming a first gap between two end faces of the first set of members, and a second set of members comprising a permanent magnetic material and located adjacent to the first set of members, wherein the second set of members provides at least a partially parallel path to the first set of members for flow of magnetic flux lines. Some embodiments may include an inductor comprising the permanent magnet hybrid core, or a power conversion circuit including a switched capacitor circuit and a switching regulator, the switching regulator including an inductance, the inductance comprising an electrical conductor wound around a permanent magnet hybrid core.
The present disclosure provides molecular time capsules (MTCs) that are selfassembled protein capsules for high-fidelity RNA capture and storage inside cytoplasm from living cells.
The present disclosure provides site- selective conjugation of a pharmaceutical agent to an antibody using an affinity peptide. The antibody-pharmaceutical agent conjugates may be useful in treating, preventing, or diagnosing diseases in subjects.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
This disclosure relates to new multi-modal sensing array architectures that can sense normal and shear forces. Examples include resistive sensing arrays that are used to measure changes in the environment and manufacturing processes to produce multi-modal sensing arrays in a highly-automated and inexpensive fashion. Specifically, a manufacturing process includes a cutting operation and sewing/embroidery technique that creates a fully automated process to produce a resistive sensing array. The new manufacturing process enables the reduction of processing time and materials to produce a functioning sensor without limiting the designs space of achievable sensor geometries. Also presented are sensor reading methodologies for high-speed reading that are capable of sensing vibrations and a wide range of forces. Examples include the use of the new sensor arrays in wearable devices.
G01L 1/20 - Measuring force or stress, in general by measuring variations in ohmic resistance of solid materials or of electrically-conductive fluidsMeasuring force or stress, in general by making use of electrokinetic cells, i.e. liquid-containing cells wherein an electrical potential is produced or varied upon the application of stress
G06F 3/045 - Digitisers, e.g. for touch screens or touch pads, characterised by the transducing means using resistive elements, e.g. a single continuous surface or two parallel surfaces put in contact
36.
METHODS AND APPARATUS FOR GENERATING COHERENT LIGHT AT NEW FREQUENCIES VIA TIME VARYING LASING
A time varying laser which can operate by taking advantage of transitions between time varying quasi-energy levels which are present in the driven system is disclosed. This can allow for laser operation at frequencies which are new, compared to the operation of the laser in absence of time-modulation. It can also allow for a novel mode of operation in which the system provides gain at multiple frequencies simultaneously, in a coherent fashion which is fundamentally different from multi-mode behavior in conventional lasers. Additionally, in systems with sufficiently strong modulation, these principles can lead to lasers which produce gain even in the thermodynamic ground state of the system, leading to a new form of lasing without inversion (LWI). In addition, these techniques have the potential to be used to create lasers at high frequencies (UV-Xray) which have been difficult to achieve via conventional laser mechanisms.
Aspects of the present disclosure relate to an article. In some embodiments, the article is a gastric retention device or a gastrointestinal device. In some embodiments, the article comprises one or more reservoirs comprising a therapeutic payload. In some embodiments, the article comprises one or more triggerable release mechanisms. In some embodiments, the triggerable release mechanism comprises a metal seal. In some embodiments, release of the therapeutic payload is accomplished via electrochemical dissolution of the metal seal. Other aspects of the disclosure relate to methods for delivering a drug using the drug delivery articles disclosed herein.
38.
PROGRAMMABLE LIPID NANOPARTICLE DELIVERY VIA CORONA PROTEIN ENGINEERING
Disclosed are compositions comprising a lipid nanoparticle and a modified biomolecular corona. In some embodiments, the modified biomolecular corona comprises a fused cell-specific binding domain. In some embodiments, the modified biomolecular corona protein has been additionally modified such that it does not bind substantially to its natural receptor. In some embodiments, the fused cell-specific binding domain binds to a target cell.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A terahertz imaging system is disclosed. The terahertz imaging system includes a terahertz antenna array, made up of a plurality of antenna elements. Each antenna element includes a patch antenna, a one bit phase shifter, and a plurality of storage elements. The storage elements are used to store a plurality of phase states that are supplied to the one bit phase shifter. The one bit phase shifter is configured to either shift the phase of the incoming signal by 90 or 270, depending on the value of the phase state. The one bit phase shifter is also bidirectional, allowing it to phase shift transmitted signals and reflected signals. A plurality of these antenna elements are disposed in a semiconductor device, where the top metal layer is exposed. This top metal layer is used to create the patch antennas.
The exponential growth in deep learning models is challenging existing computing hardware. Optical neural networks (ONNs) accelerate machine learning tasks with potentially ultrahigh bandwidth and nearly no loss in data movement. Scaling up ONNs involves improving scalability, energy efficiency, compute density, and inline nonlinearity. However, realizing all these criteria remains an unsolved challenge. Here, we demonstrate a three-dimensional spatial time-multiplexed ONN architecture based on dense arrays of microscale vertical cavity surface emitting lasers (VCSELs). The VCSELs, coherently injection-locked to a leader laser, operate at gigahertz data rates with a 7T-phase-shift voltage on the 10-millivolt level. Optical nonlinearity is incorporated into the ONN with no added energy cost using coherent detection of optical interference between VCSELs.
A cantilever may include a first dielectric layer that has a first intrinsic stress and a second dielectric layer overlying the first dielectric layer that has a second intrinsic stress that is different than the first intrinsic stress. The difference between the first and second intrinsic stresses may cause the cantilever to curve. A second dielectric layer can comprise a plurality of crossbars oriented at an angle relative to a length of the cantilever to reduce curvature in a width direction of the cantilever. The second dielectric layer can be patterned with a waveguide. The cantilever may be piezoelectrically actuated.
H10N 30/20 - Piezoelectric or electrostrictive devices with electrical input and mechanical output, e.g. functioning as actuators or vibrators
G02F 1/295 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the position or the direction of light beams, i.e. deflection in an optical waveguide structure
H01L 25/16 - Assemblies consisting of a plurality of individual semiconductor or other solid-state devices the devices being of types provided for in two or more different subclasses of , , , , or , e.g. forming hybrid circuits
The present disclosure provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides mutated Cas13 proteins and their use in modifying target sequences as well as mutated Cas13 nucleic acid sequences and vectors encoding mutated Cas13 proteins and vector systems or CRISPR-Cas13 systems.
RNA editing tools for use in systems designed to measure RNA in vivo and manipulate specific cell types are disclosed herein. An RNA sensor system comprising a) a single-stranded RNA (ssRNA) sensor comprising a stop codon and a payload; optionally wherein the ssRNA sensor further comprises a normalizing gene; and b) an adenosine deaminase acting on RNA (ADAR) deaminase; wherein the sensor is capable of binding to a ssRNA target to form a double-stranded RNA (dsRNA) duplex that becomes a substrate for the ADAR deaminase; wherein the substrate comprises a mispairing within the stop codon; and wherein the mispairing is editable by the ADAR deaminase, which editing can effectively remove the stop codon so as to enable translation and expression of the payload. A method of quantifying ribonucleic acid (RNA) levels using the RNA sensor system is also disclosed.
Methods for growing an epitaxial layer are described herein. In some embodiments, an epitaxial layer is grown over a structure comprising a crystalline substrate and a mask. The mask can be patterned with a plurality of elongated domains that help may facilitate the growth of the epitaxial layer with a reduced number of defects on the crystalline substrate. The mask may also facilitate the separation of the epitaxial layer from the crystalline substrate to form a separated epitaxial layer that is freestanding. In some embodiments, the method for growing an epitaxial layer may allow for heteroepitaxy of compound semiconductors on elemental substrates with a reduced number of defects despite polarity and/or lattice mismatches.
The invention provides for delivery, engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are delivery systems and tissues of organ which are targeted as sites for delivery. Also provided are vectors and vector systems some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provide dare methods of directing CRISPR complex formation in eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity and to edit or modify a target site in a genomic locus of interest to alter or improve the status of a disease or a condition.
Described in various embodiments herein are tiled amplification nucleic acid detection systems and uses thereof. In some embodiments, the nucleic acids amplified and detected are cell free DNA (cfDNA).
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
C12Q 1/34 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase
C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
An apparatus and method produce, from a Gaussian laser pulse, a sequence of laser rings having a spatiotemporal configuration such that impingement of the laser rings on a surface of a nuclear material in a target assembly produces constructively interfering shock waves that converge on a focal region of the nuclear material, thereby producing sufficient pressures and temperatures to form tritium in the focal region. The temporal and/or spatial intervals between the concentric pulsed laser rings are adjusted to substantially match propagation times of impingement from one ring to the next in a shock propagation layer of the target assembly. A second laser or neutron tube may be used to create a cavitation bubble at the focus. In addition to the shock waves generated in the plane of the surface, through-plane shock waves can be generated to increase the overall shock pressure.
G21G 1/12 - Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation, or particle bombardment, e.g. producing radioactive isotopes outside of nuclear reactors or particle accelerators by electromagnetic irradiation, e.g. with gamma or X-rays
G21B 1/03 - Thermonuclear fusion reactors with inertial plasma confinement
G21B 1/19 - Targets for producing thermonuclear fusion reactions
G21B 1/23 - Optical systems, e.g. for irradiating targets, for heating plasma or for plasma diagnostics
G21G 1/00 - Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation, or particle bombardment, e.g. producing radioactive isotopes
48.
SPARSE CLOSED-FORM LIQUID NEURAL ALGORITHMS FOR OUT-OF-DISTRIBUTION GENERALIZATION ON EDGE ROBOTS
According to one aspect, a system includes an autonomous agent and a sparse closed-form network. The autonomous agent has one or more cameras configured to receive images of an environment in which the agent is operating, one or more motors, and a controller configured to command the motors to move the agent with desired velocities. The sparse closed-form network is configured to process the images to determine the desired velocities for navigating the agent to a target.
49.
A NANOPORE SYSTEM AND METHOD FOR DETERMINING PROPERTIES OF NANOPARTICLES
SINGAPORE-MIT ALLIANCE FOR RESEARCH AND TECHNOLOGY CENTRE (Singapore)
NATIONAL UNIVERSITY OF SINGAPORE (Singapore)
Inventor
Garaj, Slaven
Doyle, Patrick Seamus
Li, Kun
Shah, Arjav
Shikha, Swati
Abstract
A method and system for determining mechanical properties of nanoparticles. The method comprises the steps of providing an electrically conducting fluid comprising the nanoparticles dispersed therein in a fluidic cell configured with a membrane having a nanopore extending through a thickness of the membrane; applying a voltage across the fluidic cell for effecting a translocation event of at least one of the nanoparticles through the nanopore; monitoring a current across the fluid cell for a period starting before the translocation event and ending after the translocation event to measure a current blocking signal; and determining the mechanical properties of the nanoparticles from the measured current blocking signal; wherein a size of the nanoparticles is larger than a pore size of the nanopore; and wherein an aspect ratio of thickness of the membrane to the pore size of the nanopore is smaller than 1.
Reaction schemes involving acids and bases; reactors comprising spatially varying chemical composition gradients (e.g., spatially varying pH gradients), and associated systems and methods, are generally described.
Some aspects of the present disclosure are related to modified electrodes, for example, for use in fuel cells. In some cases, the electrode may comprise a mixed-ionic-electronic-conducting (MIEC) oxide and a basic oxide. In some cases, the basic oxide may alter the electron density of the MIEC oxide and improve its catalytic performance, for example, like the oxygen reduction reaction. For instance, the catalytic performance of a MIEC oxide comprising a perovskite towards the oxygen reduction reaction (ORR) may be improved by using a basic oxide comprising CaO and/or Li2O. Some aspects disclosed herein are directed to methods of preventing or treating chromia or silica poisoning of a MIEC oxide, wherein the method comprises treating the MIEC electrode with a basic oxide infiltrant.
C12P 23/00 - Preparation of compounds containing a cyclohexene ring having an unsaturated side chain containing at least ten carbon atoms bound by conjugated double bonds, e.g. carotenes
Parameters of a first transformer are accessed, and size dimensions of a second transformer that is to be trained and is larger than the first transformer are received. The parameters of the first transformer are linearly transformed using a combination of a width-growth operator and a depth-growth operator, wherein the linear transformation produces a set of new parameters, the set corresponding to the size dimensions of the second transformer. The second transformer is initialized with the set of new parameters.
Products, such as devices, prostheses, and materials, whose surfaces have been modified in order to impart beneficial properties to these products are disclosed. The surface-modified products have improved biocompatibility compared to a corresponding product that lacks the modification. Following implantation in a subject, the surface-modified products induce a lower foreign-body response, compared to a corresponding unmodified product.
The disclosure features compositions, systems, and methods for preparation and use of efficient RNA nuclear export of ribozyme-assisted circular RNA molecules (racRNAs). In embodiments, the methods involve characterizing a cell or tissue using racRNAs.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C12N 15/66 - General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligationUse of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation
G16B 50/30 - Data warehousingComputing architectures
56.
SYSTEMS, METHODS, AND COMPOSITIONS FOR SITE-SPECIFIC GENETIC ENGINEERING USING PROGRAMMABLE ADDITION VIA SITE-SPECIFIC TARGETING ELEMENTS (PASTE)
This disclosure provides systems, methods, and compositions for site-specific genetic engineering using Programmable Addition via Site-Specific Targeting Elements (PASTE). PASTE comprises the addition of an integration site into a target genome followed by the insertion of one or more genes of interest or one or more nucleic acid sequences of interest at the site. PASTE combines gene editing technologies and integrase technologies to achieve unidirectional incorporation of genes in a genome for the treatment of diseases and diagnosis of disease.
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
Compositions including solid forms of polypeptides such as crystalline antibodies, and related methods, are generally described. The compositions may include carriers such as hydrogels that at least partially encapsulate the solid form of the polypeptides (e.g., crystals, amorphous solids). Encapsulation with certain of the materials described may result in compositions containing relatively high loadings of polypeptides while in some instances retaining structural and functional properties of the polypeptides useful for certain types of administration to subjects (e.g., for prophylactic or therapeutic applications). In some instances, compositions having relatively low dynamic viscosities while having relatively high polypeptide loadings are provided.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Described herein are muscle-specific targeting moieties and compositions including the muscle specific targeting motifs. Also described herein are uses of the muscle-specific targeting motifs and compositions including the muscle specific targeting moieties. In son embodiments, the muscle-specific targeting moieties and compositions including the muscle specific targeting moieties can be used to direct delivery of a cargo to a muscle cell.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
The present disclosure provides methods (referred to herein as "SWITCH-seq"), compositions, kits, and systems for profiling RNA expression in a cell (including, e.g., cells within an intact tissue) in both untargeted and targeted manners. Also provided by the present disclosure are methods for diagnosing a disease or disorder in a subject based on a profile of RNA expression in a cell tissue, or other biological sample. Methods of screening for or testing a candidate agent capable of modulating RNA expression are also provided by the present disclosure. The present disclosure also provides methods for treating a disease or disorder in a subject in need thereof. Oligonucleotides useful for performing the methods described herein are also provided by the present disclosure. Additionally, the present disclosure provides kits comprising any combination of the oligonucleotides described herein.
Pseudomonas aeruginosaP. aeruginosa)P. aeruginosa), which poses significant health threats to humans. From this, Applicants isolated a compound that effectively activated complement immunity to inhibit bacterial growth. Furthermore, Applicants developed a robust testing platform for complement-recruiting compounds, allowing the streamlined assessment of ternary complex formatoon and the efficacy of novel bifunctional molecules for recruiting the complement system and inhibiting bacterial growth. These findings demonstrate the potential of this approach in combating antibiotic-resistant P. aeruginosa infections, with implications for other bacterial pathogens or diseases.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
In some aspects, the present disclosure pertains to methods for the electrochemical production of NH3 from nitrogen gas and a hydrogen-containing molecule in an electrochemical cell that comprises a cathode, an anode and a lithium-ion-containing electrolyte disposed between the cathode and the anode. The electrochemical cell is operated under conditions such that lithium ions in the electrolyte are converted to lithium metal at the cathode, the lithium metal reacting with nitrogen gas to form Li3N, and the Li3N reacting with protons in a proton donor to form NH3, lithium ions and a deprotonated proton donor. Moreover, the proton donor has a Kamlet-Taft alpha parameter (α) greater than 0.7 and a Kamlet-Taft beta parameter (β) greater than 0.5. Other aspects of the present disclosure pertain to systems for electrochemical production of NH3.
The present disclosure provides cyclic silyl ethers of the formula:
The present disclosure provides cyclic silyl ethers of the formula:
The present disclosure provides cyclic silyl ethers of the formula:
and salts thereof. The cyclic silyl ethers may be useful as monomers for preparing polymers. Also described herein are polymers prepared by polymerizing a cyclic silyl ether and optionally one or more additional monomers. The polymers may be degradable (e.g., biodegradable). One or more O—Si bonds of the polymers may be the degradation sites. Also described herein are compositions and kits including the cyclic silyl ethers or polymers; methods of preparing the polymers; and methods of using the polymers, compositions, and kits.
C07F 7/08 - Compounds having one or more C—Si linkages
A61K 31/787 - Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C08G 61/06 - Macromolecular compounds containing only carbon atoms in the main chain of the macromolecule, e.g. polyxylylenes only aliphatic carbon atoms prepared by ring-opening of carbocyclic compounds
C08L 79/08 - PolyimidesPolyester-imidesPolyamide-imidesPolyamide acids or similar polyimide precursors
The present invention relates to recombinant targeting peptides, compositions comprising said targeting peptides and methods of targeted delivery of therapeutics suitable for the control, improvement and/or treatment of acne. More particularly, the present invention provides engineered targeting peptides that bind specifically to the cell wall of Cutibacterium acnes, capable of providing a homing mechanism for transporting nanoparticles comprising therapeutics to C. acnes. Accordingly, the present invention also provides methods and compositions comprising the recombinant targeting peptides for localized delivery of therapeutics to C. acnes.
C12N 9/36 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on beta-1, 4 bonds between N-acetylmuramic acid and 2-acetylamino 2-deoxy-D-glucose, e.g. lysozyme
Engineered, non-naturally occurring, RNA-targeting Type V Cas polypeptides lacking collateral cleavage activity, compositions thereof, CRISPR-Cas systems thereof, packaging and delivery systems thereof, kits thereof, and methods of use thereof, for modifying target RNA. The Type V Cas polypeptide may be a Cas 12 polypeptide, optionally a Casl2a2 polypeptide. The compositions may comprise the Type V Cas polypeptide and an engineered polypeptide comprising a tetratricopeptide repeat (TPR) domain, a DUF3800 domain and, optionally, a UvrD polypeptide and an additional TPR polypeptide. CRISPR-Cas systems may comprise the Type V Cas polypeptide, or a composition thereof, and one or more guide molecules.
Disclosed herein is a microfluidic 3D cell culture device that supports the housing and swelling of cell culture scaffolding substances without causing damage to the cells and/or cell aggregates cultured therein, optionally wherein the device has an open-top design. The device is configured to comprise networks allowing for perfusion of fluid throughout, and the configuration of the networks is tunable to the biological question being addressed. The open-top design allows for access to the cells, scaffolding substances and fluid, such that the system is amenable to easy experimental manipulation.
A respiratory monitoring system with improved detection of oxygen consumption is described. The system uses one or two mixing chambers and samples gases at selective locations for reliable detection of oxygen over extended periods of time with autonomous detection of calibration drift. The system can be used for indirect calorimetry and monitoring health of a subject.
67.
COMPOUNDS, CONJUGATES, AND COMPOSITIONS OF EPIPOLYTHIODIKETOPIPERAZINES AND POLYTHIODIKETOPIPERAZINES AND USES THEREOF
The present disclosure provides, e.g., compounds, compositions, kits, methods of synthesis, and methods of use, involving epipolythiodiketopiperazines and polythiodiketopiperazines.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
68.
Self-Configuration and Error Correction in Linear Photonic Circuits
Component errors prevent linear photonic circuits from being scaled to large sizes. These errors can be compensated by programming the components in an order corresponding to nulling operations on a target matrix X through Givens rotations X→T†X, X→XT†. Nulling is implemented on hardware through measurements with feedback, in a way that builds up the target matrix even in the presence of hardware errors. This programming works with unknown errors and without internal sources or detectors in the circuit. Modifying the photonic circuit architecture can reduce the effect of errors still further, in some cases even rendering the hardware asymptotically perfect in the large-size limit. These modifications include adding a third directional coupler or crossing after each Mach-Zehnder interferometer in the circuit and a photonic implementation of the generalized FFT fractal. The configured photonic circuit can be used for machine learning, quantum photonics, prototyping, optical switching/multicast networks, microwave photonics, or signal processing.
Described herein are medical devices and medical implements with high lubricity to flesh (or biological fluid) and/or inhibited nucleation on its surface. The device has a surface comprising an impregnating liquid and a plurality of micro-scale and/or nano-scale solid features spaced sufficiently close to stably contain the impregnating liquid therebetween. The impregnating liquid fills spaces between said solid features, the surface stably contains the impregnating liquid between the solid features, and the impregnating liquid is substantially held in place between the plurality of solid features regardless of orientation of the surface.
The present disclosure relates to compositions and methods for treating Williams syndrome (WS), herein identified as a neurodevelopmental oligodendrocyte hypomyelination-associated disease, and to compositions and methods for treatment of other neurodevelopmental myelination abnormality diseases or disorder.
A61K 31/14 - Quaternary ammonium compounds, e.g. edrophonium, choline
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/4409 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
72.
ADHESIVE MATERIAL WITH TRIGGERABLE ON-DEMAND DETACHMENT
An adhesive material that provides fast and robust adhesion on wet surfaces, where the adhesion formed is detachable on-demand. The adhesive material is formed of one or more hydrophilic polymers or copolymers grafted with one or more amine coupling groups via a plurality of cleavable physical bonds and/or cleavable covalent bonds and one or more cross linkers. Application of the adhesive material on a wet surface causes the adhesive material to absorb liquid to thereby swell the adhesive material to form a layer of hydrogel, resulting in the formation of temporary crosslinks followed by covalent crosslinks with the surface. Introducing a triggering agent cleaves the cleavable physical bonds and/or cleavable covalent bonds to allow for non-traumatic detachment of the adhesive material from the surface.
C09J 129/04 - Polyvinyl alcoholPartially hydrolysed homopolymers or copolymers of esters of unsaturated alcohols with saturated carboxylic acids
C09J 133/06 - Homopolymers or copolymers of esters of esters containing only carbon, hydrogen and oxygen, the oxygen atom being present only as part of the carboxyl radical
C09J 133/10 - Homopolymers or copolymers of methacrylic acid esters
C09J 133/26 - Homopolymers or copolymers of acrylamide or methacrylamide
C09J 151/00 - Adhesives based on graft polymers in which the grafted component is obtained by reactions only involving carbon-to-carbon unsaturated bondsAdhesives based on derivatives of such polymers
C09J 175/00 - Adhesives based on polyureas or polyurethanesAdhesives based on derivatives of such polymers
Described herein are nanoparticles comprising an LNP core with electrostatically adsorbed anionic polymers layered on the LNP surface. These nanoparticles comprise varying nucleic acid cargos and may further comprise targeting moieties covalently attached to the anionic polymers. Also provided are methods of administering cargo to a subject, methods of treatment, methods of editing a gene, and methods of reducing non-targeted cell uptake of nanoparticles.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
Systems and related methods for assisting a user to achieve postural changes and ambulation are disclosed. An assistance system may safely assist in a user's (e.g., elderly or physically disabled user) postural changes at any desired position without the need of a physical secondary body for assistance. In some embodiments, the assistance system may include front and back bases, each including a drive to help the system maneuver through an environment (e.g., home). The system may include a linkage formed of three or more links, including one link coupled to the front base and a second link coupled to the back base. In some embodiments, at least one of the joints between the links may be passive. The system may also include an actuator to control the pose of the system and safely lock the system at the desired pose to facilitate postural changes and ambulation.
A61H 3/04 - Wheeled walking aids for patients or disabled persons
A61G 5/02 - Chairs or personal conveyances specially adapted for patients or disabled persons, e.g. wheelchairs propelled by the patient or disabled person
75.
LOCALIZING, WAKING-UP, AND ESTIMATING DIRECTION OF FEMTO-SATELLITES
Femto-satellites are very small satellites that can be deployed in constellations from a larger mothership satellite for distributed measurement. They are too small to accommodate the GNSS receivers that many satellites use for navigation, but they can be located with an electromagnetic beam from the mothership satellite. The mothership satellite scans this beam across a constellation of femto-satellites. When the beam scans across a particular femto-satellite, the femto-satellite transmits an acknowledgement to the mothership satellite, e.g., by retroreflecting the beam or via a separate radio link. The beam can be modulated with commands for the femto-satellite, such as to make a measurement or transmit previously acquired data, as well with commands for determining the femto-satellite's location, such as a time stamp or beam pointing information. The femto-satellite can determine its location from the information modulated onto the beam or transmit the time stamp to the mothership satellite for localization.
B64G 3/00 - Observing or tracking cosmonautic vehicles
B64G 1/10 - Artificial satellitesSystems of such satellitesInterplanetary vehicles
B64G 1/44 - Arrangements or adaptations of power supply systems using radiation, e.g. deployable solar arrays
G01S 1/70 - Beacons or beacon systems transmitting signals having a characteristic or characteristics capable of being detected by non-directional receivers and defining directions, positions, or position lines fixed relatively to the beacon transmittersReceivers co-operating therewith using electromagnetic waves other than radio waves
G01S 5/16 - Position-fixing by co-ordinating two or more direction or position-line determinationsPosition-fixing by co-ordinating two or more distance determinations using electromagnetic waves other than radio waves
G01S 17/74 - Systems using reradiation of electromagnetic waves other than radio waves, e.g. IFF, i.e. identification of friend or foe
76.
COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E
This disclosure relates to synthetic peptides, peptidomimetics, and complexes of synthetic peptides and peptidomimetics with HLA-E, methods of making such peptides, peptidomimetics, and complexes, and methods of using such peptides, peptidomimetics and complexes for blocking, inhibiting, or preventing the interaction of HLA-E with CD94/NKG2A or activation of CD94/NKG2A by HLA-E. The synthetic peptides, peptidomimetics, and complexes of synthetic peptides and peptidomimetics with HLA-E can further comprise warheads to introduce covalent linkages between the synthetic peptides and peptidomimetics with HLA-E.
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
77.
GENERATION OF QUANTUM CONTROL PULSES AND RELATED SYSTEMS
Described is an optimal-control system and method provide an efficient routine for differentiating the most general Unitary, Liouville, or Monte-Carlo Schrödinger equation associated with the control problem of interest.
Methods and compositions for treating a cutaneous wound to treat or limit development of a pathogenic bacterial infection are provided, involving administering to a subject having a cutaneous wound an amount effective of Corynebacteria spp., or a disclosed, composition, to treat or limit development of pathogenic bacterial infection of the wound.
A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
A61K 31/7004 - Monosaccharides having only carbon, hydrogen and oxygen atoms
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The embodiments disclosed herein utilized RNA targeting effectors to provide a robust CRISPR-based diagnostic with attomolar sensitivity. Embodiments disclosed herein can detect broth DNA and RNA with comparable levels of sensitivity and can differentiate targets from non-targets based on single base pair differences. Moreover, the embodiments disclosed herein can be prepared in freeze-dried format for convenient distribution and point-of-care (POC) applications. Such embodiments are useful in multiple scenarios in human health including, for example, viral detection, bacterial strain typing, sensitive genotyping, and detection of disease-associated cell free DNA.
Described is a high-temperature superconductor (HTS) cable, comprising a plurality of HTS tapes, wherein all or part of a cross-section of at least one of the HTS tapes are removed to reduce the current carrying capacity of the HTS tape. Also described is a method for shaping the current density of a high-temperature superconductor (HTS) cable, wherein the HTS current density is carried by HTS tapes, and wherein the method comprises selective mechanical removal of all or part of the cross section of one or more of HTS tapes.
ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (USA)
PRESIDENT AND FELLOWS OF HARVARD COLLEGE (USA)
MASSACHUSETTS INSTITUTE OF TECHNOLOGY (USA)
Inventor
Green, Alexander
Braff, Dana
Takahashi, Melissa
Pardee, Keith
Collins, James J.
Lambert, Guillaume
Ferrante, Thomas
Abstract
Methods for detecting the presence of a pathogen infection are described. In particular, this document provides a method of detecting target nucleic acids, such as pathogen-specific RNA, in a biological sample obtained from a subject, where the method comprises using one or more toehold switch sensors and an isothermal amplification step to detect the target nucleic acid. Methods specific for detecting and identify the presence of a virus such as Zika virus are also provided.
C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
C12Q 1/6816 - Hybridisation assays characterised by the detection means
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
82.
THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF BACTERIAL VAGINOSIS AND METHODS OF USE THEREOF
A sequence-to-fixed-length transformation is used to process a sequence representation of a molecule structure to yield a fixed-length representation. A transformation of the fixed-length representation yields a prediction of one or more properties of the molecular structure. For example, the molecular structure is a candidate drug and the process described above is part of a screening procedure.
G16C 20/70 - Machine learning, data mining or chemometrics
G06N 3/044 - Recurrent networks, e.g. Hopfield networks
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
G01N 24/08 - Investigating or analysing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
84.
COMPOSITIONS AND METHODS FOR DELIVERING CARGO TO A TARGET CELL
Provided herein are compositions, systems, and methods for delivering cargo to a target cell. The compositions, systems, and methods comprise one or more polynucleotides encoding one or more LTR retroelement polypeptides for forming a delivery vesicle and one or more capture moieties for packaging a cargo within the delivery vesicle. The one or more LTR retroelement polypeptides for forming a delivery vesicle may comprise two or more of an LTR retroelement gag protein, a retroelement envelope protein, an LTR retroelement reverse transcriptase, or a combination thereof. The LTR retroelement polypeptide alone, the LTR retroelement envelope protein alone, or both the LTR retroelement-derived polypeptide and LTR retroelement envelope protein may be endogenous.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
Systems and methods of controlling a robot are described. In some embodiments, a method includes obtaining an input motion trajectory defining movements of the robot to perform a task and input speech corresponding with descriptions of the task. A control signal is provided to control movement of the robot based on the input motion trajectory to interact with an environment surrounding the robot with an end effector of the robot. Feedback information about the end effector resulting from the control signal is obtained, and output speech is generated by modulating the input speech based on the feedback information about the end effector.
BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (USA)
MASSACHUSETTS INSTITUTE OF TECHNOLOGY (USA)
Inventor
Barrett, Christopher, D.
Yaffe, Michael, B.
Abstract
Compositions and methods for increasing intrapleural fibrinolysis and inhibiting, treating, and/or preventing pleural space infections and/or hemothorax are disclosed.
A61K 31/145 - Amines, e.g. amantadine having sulfur atoms, e.g. thiurams (N—C(S)—S—C(S)—N or N—C(S)—S—S—C(S)—N)Sulfinylamines (—N=SO)Sulfonylamines (—N=SO2)
87.
PRE-STRESSED AND CONSTRAINED TRANSFORMABLE MATERIALS
A transformable material and comprising a base material having a natural shape, with a second material disposed on the base material in a particular pattern so as to impose a transformed shape on the base material, the transformed shape being different than the natural shape. More particularly, the base material is a stretchable 2-dimensional material, and is subjected to pre-stressing before and during disposition of the second material, whereupon after release of the stress, the stretchable base material with the disposed second material thereon automatically transform into a predetermined 3-dimensional manufactured shape.
B29C 61/06 - Making preforms having internal stresses, e.g. plastic memory
B29C 55/16 - Shaping by stretching, e.g. drawing through a dieApparatus therefor of plates or sheets multiaxial biaxial simultaneously
B29C 64/112 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using individual droplets, e.g. from jetting heads
B29K 105/00 - Condition, form or state of moulded material
88.
MEASURING REPRESENTATIONAL MOTIONS IN A MEDICAL CONTEXT
A method includes receiving data representing graphomotor motion during a succession of executions of graphomotor diagnostic tasks performed in a medical context by a subject, processing the received data using a computer, including determining a first set of quantitative features from a first execution of a task by the subject, and determining a second set of quantitative features from a second execution of a task by the subject, determining one or more metrics based on a comparison to the successive executions, including using at least the first set of quantitative features and the second set of quantitative features to determine said metrics, and providing a diagnostic report associated with neurocognitive mechanisms underlying the subject's execution of the tasks based on the determined metrics.
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/16 - Devices for psychotechnicsTesting reaction times
G06Q 10/101 - Collaborative creation, e.g. joint development of products or services
G06Q 50/00 - Information and communication technology [ICT] specially adapted for implementation of business processes of specific business sectors, e.g. utilities or tourism
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
G16H 50/00 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
89.
BULK-MATERIAL BASED FLEXIBLE THERMOELECTRIC GENERATORS FOR HEAT CONCENTRATION AND DISSIPATION
SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY (China)
Inventor
Xu, Qian
Chen, Gang
Liu, Weishu
Deng, Biao
Zhang, Pengxiang
Abstract
The present disclosure generally relates to high-performance flexible thermoelectric generators (f-TEGs) for heat concentration and dissipation. In some embodiments, the f-TEGs can be incorporated into wearable devices. The f-TEG device can include an f-TEG network of thermoelectric units that include multifunctional thin copper disks that can be used as electrodes, heat concentrators and spreaders, spacers, and flexibility enablers. Each electrode can include a spacer extending therefrom to suppress the heat loss between the hot and the cold sides through conduction and convection across a thermoelectric pillar disposed therebetween. In some embodiments, the f-TEG network can be associated with a fabric to provide good wearability and comfort even in wet thermal environments.
H10N 10/17 - Thermoelectric devices comprising a junction of dissimilar materials, i.e. devices exhibiting Seebeck or Peltier effects operating with only the Peltier or Seebeck effects characterised by the structure or configuration of the cell or thermocouple forming the device
90.
RATE OF PENETRATION/DEPTH MONITOR FOR A BOREHOLE FORMED WITH MILLIMETER-WAVE BEAM
Apparatus and methods are described for drilling deep boreholes with millimeter-wave radiation in earthen materials to access deep resources such as geothermal heat. Borehole depth and temperature at the bottom of the borehole can be monitored with probe signals and/or radiative emission from the bottom of the borehole.
E21B 47/135 - Means for transmitting measuring-signals or control signals from the well to the surface, or from the surface to the well, e.g. for logging while drilling by electromagnetic energy, e.g. of radio frequency range using light waves, e.g. infrared or ultraviolet waves
E21B 7/15 - Drilling by use of heat, e.g. flame drilling of electrically generated heat
E21B 45/00 - Measuring the drilling time or rate of penetration
E21B 47/022 - Determining slope or direction of the borehole, e.g. using geomagnetism
G01S 13/10 - Systems for measuring distance only using transmission of interrupted, pulse modulated waves
G01S 13/32 - Systems for measuring distance only using transmission of continuous waves, whether amplitude-, frequency-, or phase-modulated, or unmodulated
91.
INGESTIBLE CHEMICAL ENERGY HARVESTING SYSTEM WITH EXTENDED LIFETIME
A device is configured to be administered via an oral route by a subject. The device includes an anode, a seal disposed on the anode, and a cathode. When exposed to a liquid or a hydrogel, an exposed surface of the anode undergoes galvanic oxidation dissolution to provide DC power to the device. As the exposed surface of the anode undergoes galvanic oxidation dissolution, the seal incrementally detaches from the anode, and a substantially constant surface area of the exposed surface is maintained.
Novel design frameworks for designing electrodialysis (ED) desalination systems for purifying brackish water are provided herein. The design frameworks of the present embodiments include one or more energy management strategies, as well as recirculation-based system architectures. The design frameworks can be independent of each other, or can be used together. In some embodiments, the energy management strategy can include determining a capacity of a battery in communication with an (ED) system and imposing a charge power limit onto the battery to limit the charging rate of the ED system. The energy management strategy can be used in combination with the recirculation-based system architectures to improve efficiency of purification performed by these ED systems. These architectures can include hybrid architectures that operate in continuous flow, but provide a recirculation stream to mix the feed to achieve a desired salinity of the product stream.
C02F 1/469 - Treatment of water, waste water, or sewage by electrochemical methods by electrochemical separation, e.g. by electro-osmosis, electrodialysis, electrophoresis
93.
Streptococcus Canis Cas9 as a Genome Engineering Platform with Novel PAM Specificity
A Streptococcus canis Cas9 (ScCas9) ortholog and its engineered variants, possessing novel PAM specificity, is an addition to the family of CRISPR-Cas9 systems. ScCas9 endonuclease is used in complex with guide RNA, consisting of identical non-target-specific sequence to that of the guide RNA SpCas9, for specific recognition and activity on a DNA target immediately upstream of either an “NNGT” or “NNNGT” PAM sequence. A novel DNA-interacting loop domain within ScCas9, and other Cas9 orthologs, such as those from Streptococcus gordonii and Streptococcus angionosis facilitates a divergent PAM sequence from the “NGG” PAM of SpCas9.
C12N 1/00 - Microorganisms, e.g. protozoaCompositions thereofProcesses of propagating, maintaining or preserving microorganisms or compositions thereofProcesses of preparing or isolating a composition containing a microorganismCulture media therefor
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
C12N 15/66 - General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligationUse of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
94.
METHODS AND APPARATUS FOR AUTONOMOUS 3D SELF-ASSEMBLY, SPATIAL DOCKING AND RECONFIGURATION
A method for autonomously assembling a plurality of tiles is performed in a microgravity environment. Each tile includes a shell having a first geometrical shape and an arrangement of first magnets and a controller that are supported by the shell. The controller controls operation of the arrangement of first magnets to self-assemble the shell with another tile. The first magnets are controlled to mate with a complementary arrangement of second magnets on the other tile when the complementary arrangement of second magnets floats to within a range of magnetic attractive force of the arrangement of first magnets, with or without the aid of propulsion. The controllers in the tiles detect the status of the magnetic bonds to determine whether each pair of tiles is properly bonded or has a magnetic bond error. When an error is detected, the tiles are controlled to disassemble and reassemble to correct the error.
A system delivers, to a living subject, a therapeutic dosage of an agent; delivers, to the living subject, an on-patient medical record (OPMR) comprising a two-dimensional array of dots, encoding information about the agent, reads data from the OPMR in the living subject; applies deep learning-based image processing to the read data to generate binary array data; applies error correction to the binary data to correct errors in the binary data, thereby producing error-corrected data; and translates the error-corrected data into an estimate of the information about the agent. The deep learning-based image processing includes applying deep learning-based image binarization to the read data to produce binarized image data, and applying deep learning-based image recognition to the binarized image data to generate the binary data.
The invention relates, in part, to methods and compounds for ultrastructure membrane expansion microscopy (umExM), which permits high-resolution visualization of membrane ultrastructure using light microscopy.
The invention, in some aspects includes methods and systems for expansion microscopy. Methods of the invention permit performance of iterative expansion protocols with the simplicity of one-shot protocols, achieving ~20x expansion of cell cultures and tissues in a single expansion step, and supporting post-expansion staining of biomolecules.
Disclosed herein are capped RNA transcripts comprising one or more modified nucleotides at position +3 or higher with reference to a 5' terminus of the RNA molecule, and methods of making the same. Also provided are compositions comprising one or more of the capped RNA transcripts provided herein, and methods of using said compositions for therapeutic applications.
99.
ENGINEERED PNMA PROTEINS AND DELIVERY SYSTEMS THEREOF
Described herein are engineered paraneoplastic Ma protein (PNMA) capable of forming a capsid. In some embodiments, the engineered PNMA proteins comprise one or more modifications that enhance binding or loading of a cargo into the capsid, one or more modifications that modify cell-specificity of the capsid, one or more modifications that enhance intracellular delivery of the capsid, or a combination thereof. Also described herein are delivery systems comprising capsids comprising an engineered PNMA protein and a cargo.
Provided herein are lipid compounds of Formulae (I) and (II), and pharmaceutically acceptable salts, co-crystals, tautomers, stereoisomers, solvates, hydrates, polymorphs, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive lipid compounds, compositions, or formulations for treating and/or preventing diseases (e.g., genetic disease, proliferative disease, hematological disease, neurological disease, painful condition, psychiatric disorder, metabolic disorder, long-term medical condition, inflammatory disease, autoinflammatory disease, liver disease, lung disease, spleen disease, familial amyloid neuropathy, cardiovascular disease, viral infection, infectious disease, fibrotic condition, or autoimmune disease) in a subject, methods for synthesizing the compounds described herein, and compounds described herein synthesized by the synthetic methods described herein. The compounds are effective carriers for the delivery of an agent such as a polynucleotide (e.g., RNA) to a tissue or cell in a subject (e.g., a liver, lung, or spleen tissue/cell).
Provided herein are lipid compounds of Formulae (I) and (II), and pharmaceutically acceptable salts, co-crystals, tautomers, stereoisomers, solvates, hydrates, polymorphs, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive lipid compounds, compositions, or formulations for treating and/or preventing diseases (e.g., genetic disease, proliferative disease, hematological disease, neurological disease, painful condition, psychiatric disorder, metabolic disorder, long-term medical condition, inflammatory disease, autoinflammatory disease, liver disease, lung disease, spleen disease, familial amyloid neuropathy, cardiovascular disease, viral infection, infectious disease, fibrotic condition, or autoimmune disease) in a subject, methods for synthesizing the compounds described herein, and compounds described herein synthesized by the synthetic methods described herein. The compounds are effective carriers for the delivery of an agent such as a polynucleotide (e.g., RNA) to a tissue or cell in a subject (e.g., a liver, lung, or spleen tissue/cell).
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
C07C 233/47 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
C07D 211/14 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 233/61 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
C07D 243/08 - Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
C07D 295/13 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
